Glioblastoma multiforme is among the most frequent and lethal brain tumors. Despite the responsiveness to therapies that are advanced, tumors almost become immune and recur. Researchers at Dartmouth's Norris Cotton Cancer Center, headed by Damian A. Almiron Bonnin, MD-Ph. D. candidate of this Mark Israel laboratory, are devising strategies to reduce brain tumors from becoming immune to anti-tumor drug treatment. "During this research, we have identified a pathway that mediates the resistance of the most aggressive brain tumors, glioblastoma multiforme, to targeted anti inflammatory drugs," says Almiron Bonnin. "Significantly, there are drugs currently available that can block this pathway to immunity." The research finds that insulin signaling functions as a "tumor-growth signal" in brain cancer cells which have been treated with a targeted anti-tumor treatment, thus allowing the tumor to grow despite continued treatment. Resistance is prevented by